Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Fluoroquinolone Antibiotic — Ophthalmic

Moxifloxacin Eye Drops 0.5%

Brand names: Moxeza, Vigamox

Moxifloxacin eye drops are a topical fourth-generation fluoroquinolone antibacterial used to treat bacterial conjunctivitis and other susceptible ocular surface infections.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription and repair, producing a bactericidal effect.

Prescribing in practice

  • Reserve for confirmed or strongly suspected bacterial infection and limit the duration of treatment to reduce selection of fluoroquinolone resistance.
  • It is not indicated for prophylaxis of, or treatment for, viral or fungal eye infections.
  • Some formulations are preservative-free, but where a preservative is present contact lens wear is generally avoided during active infection.

Monitoring

Response is assessed clinically, and treatment should be reviewed if the infection fails to improve within a few days.

Counselling the patient

  • Complete the prescribed course even if the eye looks better, and do not share the bottle.
  • Avoid wearing contact lenses until the infection has cleared and your clinician agrees.
  • Seek review if symptoms worsen or do not improve as expected.

Evidence & guidelines

Topical fluoroquinolones are an established treatment for bacterial conjunctivitis, supported by clinical trials and the SPC.

Reference: ESCRS Endophthalmitis Trial; NICE Guidelines (Conjunctivitis); SPC Vigamox; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways